ALK and non-small cell lung carcinoma: Furthermore, PFS was more severe in patients with TP53 co-mutations than in patients with wild-type TP53, meaning the combination of proteasome inhibitors with alectinib is a promising therapy for NSCLC with ALK rearrangement/TP53 mutations (49, 140).